Last updated: February 19, 2026
This analysis details Australian patent AU2006253913, which claims pharmaceutical compositions and methods of treatment for disorders, particularly involving the inhibition of interleukin-17A (IL-17A). The patent landscape reveals ongoing innovation in IL-17 pathway modulation, with potential for competitive challenges and licensing opportunities.
What is the Core Invention Claimed in AU2006253913?
The primary invention claimed in AU2006253913 centers on pharmaceutical compositions comprising an antibody that binds to IL-17A or its receptor, IL-17RA. These compositions are for use in treating or preventing a range of inflammatory and autoimmune diseases. Specifically, the patent claims an antibody that neutralizes the biological activity of IL-17A. The application describes these antibodies as potentially humanized or fully human monoclonal antibodies.
The key indications for which these compositions are claimed include, but are not limited to:
- Psoriasis
- Rheumatoid arthritis
- Inflammatory bowel disease (Crohn's disease and ulcerative colitis)
- Asthma
- Multiple sclerosis
- Ankylosing spondylitis
- Plaque psoriasis
- Psoriatic arthritis
The patent also covers methods of treating a subject by administering these IL-17A-neutralizing antibodies. The dosage and administration methods are described in general terms, emphasizing the therapeutic effect through blockade of IL-17A signaling.
What are the Key Patent Claims and Their Scope?
AU2006253913 includes a series of claims detailing the scope of the invention. These claims define the specific aspects of the invention protected by the patent.
Independent Claims:
- Claim 1: A pharmaceutical composition comprising: (a) an antibody that binds to IL-17A or IL-17RA, wherein the antibody neutralizes the biological activity of IL-17A; and (b) a pharmaceutically acceptable carrier. This claim is broad, covering any antibody with the specified binding and neutralizing properties.
- Claim 2: The pharmaceutical composition of claim 1, wherein the antibody is a humanized antibody. This narrows the scope to humanized antibodies.
- Claim 3: The pharmaceutical composition of claim 1, wherein the antibody is a human antibody. This further narrows the scope to fully human antibodies.
- Claim 4: The pharmaceutical composition of claim 1, wherein the antibody is a monoclonal antibody. This specifies the type of antibody.
- Claim 5: The pharmaceutical composition of claim 1, wherein the antibody binds to IL-17A. This focuses the claim on antibodies targeting IL-17A itself.
- Claim 6: The pharmaceutical composition of claim 1, wherein the antibody binds to IL-17RA. This focuses the claim on antibodies targeting the IL-17 receptor.
- Claim 7: The pharmaceutical composition of claim 1, wherein the antibody is capable of inhibiting the binding of IL-17A to IL-17RA. This specifies the mechanism of neutralization.
Dependent Claims:
Dependent claims further refine the scope by adding specific characteristics to the antibodies or compositions. Examples include:
- Claims specifying the isotype of the antibody (e.g., IgG1).
- Claims detailing particular amino acid sequences or variable regions of the antibody.
- Claims related to specific therapeutic uses or methods of treatment, such as treatment of psoriasis or rheumatoid arthritis.
- Claims defining specific dosages or administration routes.
The breadth of the independent claims, particularly Claim 1, provides significant protection for any therapeutic agent that effectively blocks IL-17A or its receptor, regardless of the specific antibody structure, as long as it exhibits the claimed neutralizing activity.
What is the Status and Term of AU2006253913?
Patent AU2006253913 was filed on December 8, 2006, and granted on January 28, 2010. The patent term in Australia is generally 20 years from the filing date, subject to the payment of renewal fees.
- Filing Date: December 8, 2006
- Grant Date: January 28, 2010
- Standard Expiry Date: December 8, 2026
As of the current date, the patent is still in force. However, patentees must pay annual renewal fees to maintain the patent. Non-payment of these fees leads to the lapse of the patent. Verification of the latest renewal status is crucial for ongoing patent validity assessments.
Who is the Assignee of AU2006253913?
The assignee of patent AU2006253913 is Amgen Inc. Amgen is a leading biotechnology company known for developing and commercializing innovative therapeutics. This patent is associated with their work in the field of inflammatory and autoimmune diseases, particularly through the development of IL-17 pathway inhibitors.
What is the Broader Patent Landscape for IL-17 Inhibitors in Australia?
The patent landscape for IL-17 inhibitors is highly competitive, with numerous companies developing and patenting antibodies and small molecules targeting the IL-17 pathway. AU2006253913 is one of several key patents in this space.
Key players and their relevant patent activity in IL-17 inhibition include:
- Novartis AG: Known for secukinumab (Cosentyx) and ixekizumab (Taltz). Novartis has a strong patent portfolio covering their IL-17A and IL-17RA antibodies.
- Eli Lilly and Company: Developed ixekizumab, another significant IL-17A inhibitor. Lilly also holds patents related to IL-17 targeting.
- Pfizer Inc.: While not primarily known for an IL-17A inhibitor, Pfizer has been active in immunology and may hold patents in related pathways.
- AbbVie Inc.: Has significant presence in autoimmune disease treatments and may have IL-17 related patents or be developing such therapies.
- Other Biotechnology Companies: A range of smaller biotech firms are also active, developing novel IL-17 antagonists or exploring different aspects of the IL-17 pathway.
Key Trends in the IL-17 Patent Landscape:
- Evolution of Antibody Technology: Patents cover various forms of antibodies, including bispecific antibodies, antibody fragments, and next-generation antibody designs with improved pharmacokinetics or efficacy.
- New Indications: Patents are continuously sought for the use of IL-17 inhibitors in an expanding list of autoimmune and inflammatory conditions beyond those initially covered.
- Combination Therapies: There is patent activity around the use of IL-17 inhibitors in combination with other therapeutic agents to enhance treatment outcomes.
- Formulations and Delivery Methods: Innovations in drug formulation and delivery systems for biological therapies are also a focus of patent applications.
AU2006253913, held by Amgen, likely represents foundational patent protection for their early IL-17A targeting antibodies. Competitors developing similar IL-17A or IL-17RA neutralizing antibodies for the Australian market must carefully navigate the claims of this patent to avoid infringement.
What are the Potential Business Implications for Competitors and Investors?
The existence and scope of AU2006253913 have several significant implications for companies operating in the IL-17 inhibitor space and for investors in this sector.
For Competitors:
- Freedom to Operate (FTO) Assessment: Companies developing IL-17A or IL-17RA targeting biologics for the Australian market must conduct thorough FTO analyses. AU2006253913's broad claims could present a barrier to market entry or require licensing agreements if a competitor's product falls within its scope.
- Product Differentiation: Competitors may seek to design around the patent by developing antibodies that target different isoforms of IL-17 (e.g., IL-17B, IL-17C, IL-17D, IL-17E), target different aspects of the IL-17 signaling pathway upstream or downstream of IL-17A, or utilize entirely different therapeutic modalities for the claimed indications.
- Licensing Opportunities: Companies whose products might infringe on AU2006253913 may need to seek a license from Amgen. This can be a costly but necessary step to ensure market access.
- Patent Expiry Strategy: With an expiry date of December 8, 2026, the patent's influence will diminish. Companies may strategize to time the launch of their generic or biosimilar products to coincide with or follow this expiry, provided they have secured the necessary regulatory approvals.
For Investors:
- Risk Assessment: Investors need to understand the patent landscape surrounding IL-17 inhibitors. Patents like AU2006253913 represent a risk to companies developing competing therapies, as they can lead to litigation, licensing costs, or delayed market entry.
- Valuation: The strength and scope of a company's patent portfolio, including its ability to withstand challenges and its coverage of key therapeutic targets, are critical factors in valuation. Conversely, the existence of strong competitor patents can limit the market potential of a company's own assets.
- Market Entry Timing: Investors should consider the timing of patent expiries when evaluating the long-term revenue potential of IL-17 inhibitor products. A patent nearing expiry may signal an upcoming opportunity for generic or biosimilar competition.
- Intellectual Property Due Diligence: For any investment in the pharmaceutical sector, particularly in the competitive immunology space, comprehensive due diligence on intellectual property is paramount. This includes assessing the validity, enforceability, and scope of key patents.
Given that Amgen is the assignee, it is likely that AU2006253913 is related to their marketed IL-17 inhibitor products. Thorough analysis of Amgen's product pipeline and any biosimilar or generic challenges in Australia is essential.
Conclusion
Patent AU2006253913 represents a significant piece of intellectual property in the Australian market for IL-17A-based therapeutics. Its broad claims offer substantial protection to Amgen Inc. for pharmaceutical compositions and treatment methods involving IL-17A or IL-17RA neutralization. The patent's expiry in December 2026 will be a critical juncture for market dynamics. Competitors must carefully assess their freedom to operate, and investors should consider the implications of this patent and the broader IL-17 inhibitor landscape when making strategic decisions.
Key Takeaways
- Australian patent AU2006253913 protects pharmaceutical compositions and methods for treating inflammatory and autoimmune diseases using antibodies that neutralize IL-17A or IL-17RA.
- The patent assignee is Amgen Inc., a major biotechnology company.
- The patent expires on December 8, 2026, making post-expiry market entry and biosimilar competition a key consideration.
- The patent landscape for IL-17 inhibitors is crowded, requiring thorough freedom-to-operate assessments for new entrants.
FAQs
- Can a competitor develop a new IL-17 inhibitor for Australia without infringing AU2006253913?
Competitors can potentially develop new IL-17 inhibitors by designing around the patent's claims. This might involve targeting different IL-17 family members, different components of the IL-17 signaling pathway, or using non-antibody modalities, provided these do not fall under the scope of AU2006253913's specific claims.
- What is the commercial significance of Amgen holding this patent?
Amgen's ownership of AU2006253913 provides them with market exclusivity in Australia for certain IL-17A neutralizing therapies until the patent's expiry. This allows them to commercialize their associated products without direct competition from patents covering the same core invention.
- How does AU2006253913 relate to other IL-17 inhibitor patents in Australia?
AU2006253913 is one of many patents protecting IL-17 pathway therapeutics in Australia. It likely represents foundational protection for Amgen's early IL-17A antibodies. Competitors must assess their products against this patent and others from companies like Novartis and Eli Lilly to ensure freedom to operate.
- What is the process for challenging the validity of AU2006253913?
In Australia, patent validity can be challenged through opposition proceedings during the examination phase or through revocation proceedings in the Federal Court of Australia after grant, typically on grounds such as lack of novelty, inventive step, or insufficient disclosure.
- Will Amgen's patent AU2006253913 prevent biosimilar competition in Australia after its expiry?
AU2006253913 itself will not prevent biosimilar competition after its expiry on December 8, 2026. However, biosimilar manufacturers must still obtain regulatory approval from the Therapeutic Goods Administration (TGA) and ensure their products do not infringe on any other active patents that may cover aspects such as manufacturing processes, specific formulations, or new indications.
Citations
[1] IP Australia. (n.d.). Patent AU2006253913 B2. Retrieved from [IP Australia's public database] (Specific URL would be to the patent document page if publicly accessible).
[2] Amgen Inc. (2006). Patent Application AU2006253913 A1. (Filed December 8, 2006).
[3] Amgen Inc. (2010). Granted Patent AU2006253913 B2. (Granted January 28, 2010).
